Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort
- Shaw, Dominick E.
- Sousa, Ana R.
- Fowler, Stephen J.
- Fleming, Louise J.
- Roberts, Graham
- Corfield, Julie
- Pandis, Ioannis
- Bansal, Aruna T.
- Bel, Elisabeth H.
- Auffray, Charles
- Compton, Chris H.
- Bisgaard, Hans
- Bucchioni, Enrica
- Caruso, Massimo
- Chanez, Pascal
- Dahlen, Barbro
- Dahlen, Sven-Erik
- Dyson, Kerry
- Frey, Urs
- Geiser, Thomas
- Gerhardsson de Verdier, Maria
- Gibeon, David
- Guo, Yi-ke
- Hashimoto, Simone
- Hedlin, Gunilla
- Jeyasingham, Elizabeth
- Hekking, Pieter-Paul W.
- Higenbottam, Tim
- Horváth, Ildikó
- Knox, Alan J.
- Krug, Norbert
- Erpenbeck, Veit J.
- Larsson, Lars X.
- Lazarinis, Nikos
- Matthews, John G.
- Middelveld, Roelinde
- Montuschi, Paolo
- Musial, Jacek
- Myles, David
- Pahus, Laurie
- Sandström, Thomas
- Seibold, Wolfgang
- Singer, Florian
- Strandberg, Karin
- Vestbo, Jorgen
- Vissing, Nadja
- von Garnier, Christophe
- Adcock, Ian M.
- Wagers, Scott
- Rowe, Anthony
- Howarth, Peter
- Wagener, Ariane H.
- Djukanovic, Ratko
- Sterk, Peter J.
- Chung, Kian Fan
DOIAbstract
U-BIOPRED is a European Union consortium of 20 academic institutions, 11 pharmaceutical companies and six patient organisations with the objective of improving the understanding of asthma disease mechanisms using a systems biology approach. This cross-sectional assessment of adults with severe asthma, mild/moderate asthma and healthy controls from 11 European countries consisted of analyses of patient-reported outcomes, lung function, blood and airway inflammatory measurements. Patients with severe asthma (nonsmokers, n=311; smokers/ex-smokers, n=110) had more symptoms and exacerbations compared to patients with mild/moderate disease (n=88) (2.5 exacerbations versus 0.4 in the preceding 12 months; p<0.001), with worse quality of life,...
Add to ORKG